Journal
CLINICAL AND VACCINE IMMUNOLOGY
Volume 23, Issue 12, Pages 904-907Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/CVI.00444-16
Keywords
-
Categories
Ask authors/readers for more resources
Shigella spp. represent the second most common etiologic pathogen causing childhood diarrhea in developing countries. There are no licensed Shigella vaccines, and progress for such vaccines has been limited. In this issue of Clinical and Vaccine Immunology, Riddle and colleagues (M.S. Riddle, R.W. Kaminski, C. Di Paolo, C.K. Porter, R.L. Gutierrez, et al., Clin Vaccine Immunol 23: 908-917, 2016, http://dx.doi.org/10.1128/CVI.00224-16) report results from a phase I study of a parenterally administered monovalent O-polysaccharide bioconjugate directed against Shigella flexneri 2a. Ultimately, the goal is to develop a broad-spectrum Shigella vaccine to address this public health concern. A parenteral Shigella vaccine capable of eliciting protection in children of developing countries would be an important tool to reach this goal.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available